Article

SOM Biotech SL Announces New Logo and Website Launch

The new and completely redesigned website offers quick and easy access to essential and relevant information on SOM Biotech. This renewed design is aligned with the ambitious stage SOM Biotech is currently entering. After closing a successful €2M round and with its first large program out licensed (SOM0226 for TTR Amyloidosis), SOM Biotech is going through an exciting growth stage with the aim to be a global leader in the field of Repurposing Drugs for Orphan Diseases. Next $10M Series A are already opened to investors willing to participate in a uniquely capital/risk efficient business plan. www.sombiotech.com